Row over Mylan EpiPen boils down to plastic cap
Firm urges FDA to approve Teva's generic devices only if they were truly equivalent and wouldn't confuse patients
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Washington
THE lack of a cheaper version of Mylan NV's EpiPen shot may come down to a dispute between drugmakers over a plastic cap.
Unlike Mylan's one-cap EpiPen, Teva Pharmaceutical Industries' proposed substitutable generic version has two caps, including a removable one that covers the spot where its needle extends. In a petition to the US Food and Drug Administration (FDA), Mylan cited that difference as the key reason the agency should reject Teva's generic - which is exactly what happened in February of this year.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
OCBC is said to emerge as lead bidder for HSBC Indonesia assets
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
